TAK logo

TAK Free cash flow

annual FCF:

$4.03B+$2.93B(+265.32%)
March 1, 2025

Summary

  • As of today (August 16, 2025), TAK annual free cash flow is $4.03 billion, with the most recent change of +$2.93 billion (+265.32%) on March 1, 2025.
  • During the last 3 years, TAK annual FCF has fallen by -$3.40 billion (-45.75%).
  • TAK annual FCF is now -45.75% below its all-time high of $7.43 billion, reached on March 31, 2022.

Performance

TAK Free cash flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTAKcash flow metrics

quarterly FCF:

$970.52M+$115.74M(+13.54%)
June 1, 2025

Summary

  • As of today (August 16, 2025), TAK quarterly free cash flow is $970.52 million, with the most recent change of +$115.74 million (+13.54%) on June 1, 2025.
  • Over the past year, TAK quarterly FCF has increased by +$862.66 million (+799.86%).
  • TAK quarterly FCF is now -67.12% below its all-time high of $2.95 billion, reached on March 31, 2022.

Performance

TAK quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTAKcash flow metrics

TTM FCF:

$5.31B+$862.66M(+19.39%)
June 1, 2025

Summary

  • As of today (August 16, 2025), TAK TTM free cash flow is $5.31 billion, with the most recent change of +$862.66 million (+19.39%) on June 1, 2025.
  • Over the past year, TAK TTM FCF has increased by +$2.28 billion (+75.32%).
  • TAK TTM FCF is now -36.37% below its all-time high of $8.35 billion, reached on March 31, 2022.

Performance

TAK TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTAKcash flow metrics

Free cash flow Formula

FCF = Cash From Operations − CAPEX

TAK Free cash flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+265.3%+799.9%+75.3%
3 y3 years-45.8%+989.7%-25.2%
5 y5 years+29.8%-0.9%+19.9%

TAK Free cash flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-45.8%+265.3%-57.8%+175.3%-25.2%+751.8%
5 y5-year-45.8%+265.3%-67.1%+175.3%-36.4%+751.8%
alltimeall time-45.8%+930.4%-67.1%+169.4%-36.4%+603.5%

TAK Free cash flow History

DateAnnualQuarterlyTTM
Jun 2025
-
$970.52M(+13.5%)
$5.31B(+19.4%)
Mar 2025
$4.03B(+265.3%)
$854.77M(-59.4%)
$4.45B(-12.5%)
Dec 2024
-
$2.11B(+52.6%)
$5.08B(+47.2%)
Sep 2024
-
$1.38B(+1179.7%)
$3.45B(+14.0%)
Jun 2024
-
$107.85M(-92.8%)
$3.03B(+85.5%)
Mar 2024
$1.10B(-38.6%)
$1.49B(+212.2%)
$1.63B(-300.4%)
Dec 2023
-
$476.74M(-50.2%)
-$814.80M(-180.8%)
Sep 2023
-
$956.59M(-174.2%)
$1.01B(-26.1%)
Jun 2023
-
-$1.29B(+34.3%)
$1.36B(-46.4%)
Mar 2023
$1.80B(-75.8%)
-$959.41M(-141.7%)
$2.54B(-60.6%)
Dec 2022
-
$2.30B(+75.2%)
$6.45B(-3.6%)
Sep 2022
-
$1.31B(-1303.2%)
$6.70B(-5.7%)
Jun 2022
-
-$109.09M(-103.7%)
$7.10B(-14.9%)
Mar 2022
$7.43B(+17.9%)
$2.95B(+16.2%)
$8.35B(+3.7%)
Dec 2021
-
$2.54B(+48.0%)
$8.05B(+11.4%)
Sep 2021
-
$1.72B(+50.9%)
$7.23B(-3.2%)
Jun 2021
-
$1.14B(-57.2%)
$7.46B(+2.2%)
Mar 2021
$6.30B(+103.0%)
$2.66B(+54.8%)
$7.31B(+26.5%)
Dec 2020
-
$1.72B(-12.1%)
$5.78B(+25.0%)
Sep 2020
-
$1.95B(+99.3%)
$4.62B(+4.4%)
Jun 2020
-
$979.32M(-13.3%)
$4.43B(+6.5%)
Mar 2020
$3.11B(+104.4%)
$1.13B(+100.6%)
$4.16B(+12.2%)
Dec 2019
-
$562.75M(-68.0%)
$3.71B(+0.5%)
Sep 2019
-
$1.76B(+148.5%)
$3.69B(+52.8%)
Jun 2019
-
$707.93M(+4.7%)
$2.41B(+37.7%)
Mar 2019
$1.52B(-33.0%)
$676.10M(+24.3%)
$1.75B(-12.8%)
Dec 2018
-
$544.05M(+12.1%)
$2.01B(-1.0%)
Sep 2018
-
$485.30M(+916.4%)
$2.03B(+8.1%)
Jun 2018
-
$47.75M(-94.9%)
$1.88B(-16.6%)
Mar 2018
$2.27B(+65.9%)
$933.11M(+65.5%)
$2.25B(+6.3%)
Dec 2017
-
$563.90M(+69.2%)
$2.12B(+50.5%)
Sep 2017
-
$333.21M(-21.1%)
$1.41B(-4.0%)
Jun 2017
-
$422.46M(-47.1%)
$1.47B(+6.2%)
Mar 2017
$1.37B(-381.6%)
$798.90M(-644.4%)
$1.38B(-269.0%)
Dec 2016
-
-$146.74M(-137.4%)
-$816.88M(+268.8%)
Sep 2016
-
$392.19M(+16.5%)
-$221.51M(+20.9%)
Jun 2016
-
$336.58M(-124.1%)
-$183.21M(-63.0%)
Mar 2016
-$485.53M
-$1.40B(-411.8%)
-$494.72M(-148.4%)
Dec 2015
-
$448.64M(+4.2%)
$1.02B(+15.5%)
DateAnnualQuarterlyTTM
Sep 2015
-
$430.48M(+1617.2%)
$884.98M(-9.1%)
Jun 2015
-
$25.07M(-78.7%)
$973.73M(+44.3%)
Mar 2015
$680.19M(-2.4%)
$117.69M(-62.2%)
$674.86M(-51.3%)
Dec 2014
-
$311.74M(-40.0%)
$1.39B(+2.1%)
Sep 2014
-
$519.23M(-289.6%)
$1.36B(-8.4%)
Jun 2014
-
-$273.80M(-133.0%)
$1.48B(+111.4%)
Mar 2014
$696.96M(-73.8%)
$829.11M(+193.2%)
$700.90M(-646.7%)
Dec 2013
-
$282.76M(-56.1%)
-$128.20M(-68.8%)
Sep 2013
-
$643.77M(-161.0%)
-$410.96M(-61.0%)
Jun 2013
-
-$1.05B(-189.2%)
-$1.05B(-144.8%)
Mar 2013
$2.66B(-23.6%)
-
-
Mar 2012
$3.48B(+46.9%)
-
-
Mar 2011
$2.37B(-25.3%)
$1.18B(+176.1%)
$2.36B(+20.6%)
Dec 2010
-
$428.34M(-49.4%)
$1.95B(-10.2%)
Sep 2010
-
$845.79M(-930.1%)
$2.18B(-8.3%)
Jun 2010
-
-$101.89M(-113.0%)
$2.37B(-25.2%)
Mar 2010
$3.17B(+11.1%)
$781.13M(+20.2%)
$3.17B(+32.7%)
Dec 2009
-
$650.04M(-37.7%)
$2.39B(+37.4%)
Sep 2009
-
$1.04B(+49.7%)
$1.74B(+149.7%)
Jun 2009
-
$696.73M
$696.73M
Mar 2009
$2.85B(+25.4%)
-
-
Mar 2008
$2.27B(+47.6%)
-
-
Mar 2007
$1.54B(-48.9%)
-
-
Mar 2006
$3.02B(+34.1%)
-
-
Mar 2005
$2.25B(-1.0%)
-
-
Mar 2004
$2.27B(+20.5%)
-
-
Mar 2003
$1.89B(+16.1%)
-
-
Mar 2002
$1.63B(-3.2%)
-
-
Mar 2001
$1.68B(+51.4%)
-
-
Mar 2000
$1.11B(+85.4%)
-
-
Mar 1999
$598.49M(-2.1%)
-
-
Mar 1998
$611.51M(+10.8%)
-
-
Mar 1997
$552.09M(-3.6%)
-
-
Mar 1996
$572.50M(+65.0%)
-
-
Mar 1995
$347.07M(-39.1%)
-
-
Mar 1994
$569.52M(+232.2%)
-
-
Mar 1993
$171.46M(-44.8%)
-
-
Mar 1992
$310.79M(+961.7%)
-
-
Mar 1991
$29.27M
-
-

FAQ

  • What is Takeda Pharmaceutical Company Limited annual free cash flow?
  • What is the all time high annual FCF for Takeda Pharmaceutical Company Limited?
  • What is Takeda Pharmaceutical Company Limited annual FCF year-on-year change?
  • What is Takeda Pharmaceutical Company Limited quarterly free cash flow?
  • What is the all time high quarterly FCF for Takeda Pharmaceutical Company Limited?
  • What is Takeda Pharmaceutical Company Limited quarterly FCF year-on-year change?
  • What is Takeda Pharmaceutical Company Limited TTM free cash flow?
  • What is the all time high TTM FCF for Takeda Pharmaceutical Company Limited?
  • What is Takeda Pharmaceutical Company Limited TTM FCF year-on-year change?

What is Takeda Pharmaceutical Company Limited annual free cash flow?

The current annual FCF of TAK is $4.03B

What is the all time high annual FCF for Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited all-time high annual free cash flow is $7.43B

What is Takeda Pharmaceutical Company Limited annual FCF year-on-year change?

Over the past year, TAK annual free cash flow has changed by +$2.93B (+265.32%)

What is Takeda Pharmaceutical Company Limited quarterly free cash flow?

The current quarterly FCF of TAK is $970.52M

What is the all time high quarterly FCF for Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited all-time high quarterly free cash flow is $2.95B

What is Takeda Pharmaceutical Company Limited quarterly FCF year-on-year change?

Over the past year, TAK quarterly free cash flow has changed by +$862.66M (+799.86%)

What is Takeda Pharmaceutical Company Limited TTM free cash flow?

The current TTM FCF of TAK is $5.31B

What is the all time high TTM FCF for Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited all-time high TTM free cash flow is $8.35B

What is Takeda Pharmaceutical Company Limited TTM FCF year-on-year change?

Over the past year, TAK TTM free cash flow has changed by +$2.28B (+75.32%)
On this page